Prosecution Insights
Last updated: November 20, 2026

Meera Natarajan, USPTO Patent Examiner

Listed by the USPTO as NATARAJAN, MEERA

Tech Center 1600 • Art Units: 1643 1645 1646 1674

This examiner grants 63% of resolved cases

Analysis

NATARAJAN, MEERA is a USPTO patent examiner in Tech Center 1600 and Art Unit 1643. The profile records 769 resolved cases, a 62.7% allowance rate, and a median of 1178 days to allowance. This volume gives practitioners a broad historical record for assessing prosecution posture and expected timing.

The interview lift is 17.8%, providing a basis for considering interviews alongside claim amendments and written responses. The listed companies are Santersus AG, Xencor Inc., and Hoffmann-La Roche Inc. The listed firms are MEDLER FERRO WOODHOUSE & MILLS PLLC, TROUTMAN PEPPER LOCKE LLP, and MARSHALL, GERSTEIN & BORUN LLP.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

62.7%
Allow Rate
+2.7% vs TC avg
822
Total Applications
+17.8%
Interview Lift
1178
Avg Prosecution Days
Based on 769 resolved cases, 2023–2026

Rejection Statute Breakdown

3.5%
§101 Eligibility
16.3%
§102 Novelty
27.4%
§103 Obviousness
28.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18627727 COMBINED ADMINISTRATION Non-Final OA Hoffmann-La Roche Inc.
18528157 ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF Non-Final OA Janssen Biotech, Inc.
17997482 ENGINEERED IMMUNOGLOBULINS Final Rejection Novartis AG
17969033 METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST Non-Final OA REGENERON PHARMACEUTICALS, INC.
18224865 GENERATION OF ANTI-TUMOR T CELLS Non-Final OA Dana-Farber Cancer Institute, Inc.
18338313 NOVEL METHOD FOR PRODUCING ANTIBODIES Non-Final OA TSINGHUA UNIVERSITY
18430415 BISPECIFIC ANTIBODY CONSTRUCTS FOR CDH3 AND CD3 Non-Final OA AMGEN RESEARCH (MUNICH) GMBH
18690886 USE OF ANTI-CD40 ANTIBODY Non-Final OA CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
18480038 ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER Non-Final OA Arizona Board of Regents on Behalf of Arizona State University
18639592 COMPOSITIONS AND METHODS FOR MODULATING HYDROXYLATION OF ACC2 BY PHD3 Non-Final OA President and Fellows of Harvard College
18558882 DOUBLE SIDED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED CELL MEMBRANE BASED DRUG DELIVERY SYSTEMS Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
18705759 COMPOSITIONS FOR CELL-BASED THERAPIES AND RELATED METHODS Non-Final OA SIGILON THERAPEUTICS, INC.
18290668 NOVEL CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELLS EXPRESSING SAME Non-Final OA KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Meera Natarajan's allowance rate?

62.7% of resolved applications examined by Meera Natarajan were allowed (769 resolved cases), compared with 41.5% across Art Unit 1643 over the last five years.

Does an interview help with examiner Meera Natarajan?

This examiner's interview lift is +17.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Meera Natarajan take to allow a patent?

Applications allowed by Meera Natarajan took 1,178 days on average from filing to allowance.

Which art unit does examiner Meera Natarajan work in?

Meera Natarajan examines applications in Art Unit 1643 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month